AN ACUTE ABDOMEN MASQUERADING A RARE FORM OF APPENDICULAR NEOPLASIA
Keywords:
acute appendicitis, appendiceal neoplasia, goblet cell carcinoma
Abstract
Appendix neoplasia is an uncommon and in many cases aggressive form of malignancy. Goblet cell carcinoma is found incidentally after appendectomies for acute appendicitis and it is frequent in an advanced stage. There are a lot of controversy regarding the proper management of a patient diagnosed with goblet cell carcinoma. We present the case of a 48-years old male patient with an aggressive form of appendiceal goblet cell carcinoma found after appendectomy, with a favorable outcome after completion with right hemicolectomy and adjuvant chemotherapy. Further trials and studies should bring more light to the proper guidelines for treatment of this particular neoplasia.
References
[1] S. Marmor, P. R. Portschy, T. M. Tuttle, and B. A. Virnig, “The Rise in Appendiceal Cancer Incidence: 2000–2009,” J. Gastrointest. Surg., vol. 19, no. 4, pp. 743–750, 2015, doi: 10.1007/s11605-014-2726-7.
[2] K. Walsh, N. Ojha, A. Nat, L. Gitto, and V. Untanu, “A Rare Presentation of Appendiceal Carcinoma.,” Cureus, vol. 13, no. 7. p. e16370, Jul. 2021, doi: 10.7759/cureus.16370.
[3] M. L. McGory, M. A. Maggard, H. Kang, J. B. O’Connell, and C. Y. Ko, “Malignancies of the appendix: beyond case series reports.,” Dis. Colon Rectum, vol. 48, no. 12, pp. 2264–2271, Dec. 2005, doi: 10.1007/s10350-005-0196-4.
[4] K. J. Kelly, “Management of Appendix Cancer,” Clin. Colon Rectal Surg., vol. 28, no. 4, pp. 247–255, 2015, doi: 10.1055/s-0035-1564433.
[5] U.-F. Pape et al., “ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.,” Neuroendocrinology, vol. 95, no. 2, pp. 135–156, 2012, doi: 10.1159/000335629.
[6] M. J. Snyder, M. Guthrie, and S. Cagle, “Acute Appendicitis: Efficient Diagnosis and Management.,” Am. Fam. Physician, vol. 98, no. 1, pp. 25–33, Jul. 2018.
[7] A. Lamarca et al., “Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence.,” Neuroendocrinology, vol. 103, no. 5, pp. 500–517, 2016, doi: 10.1159/000440725.
[8] S. Edition, S. B. Edge, and D. R. Byrd, “AJCC cancer staging manual,” AJCC cancer staging Man., 2017.
[9] T. H. Pham, B. Wolff, S. C. Abraham, and E. Drelichman, “Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience.,” Ann. Surg. Oncol., vol. 13, no. 3, pp. 370–376, Mar. 2006, doi: 10.1245/ASO.2006.02.016.
[10] K. Palmer et al., “Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry,” Front. Oncol., vol. 12, no. July, pp. 1–14, 2022, doi: 10.3389/fonc.2022.915028.
[11] M. Yozu et al., “Histologic and Outcome Study Supports Reclassifying Appendiceal Goblet Cell Carcinoids as Goblet Cell Adenocarcinomas, and Grading and Staging Similarly to Colonic Adenocarcinomas.,” Am. J. Surg. Pathol., vol. 42, no. 7, pp. 898–910, Jul. 2018, doi: 10.1097/PAS.0000000000001056.
[12] M. Pericleous et al., “Appendiceal goblet cell carcinoid tumour: a case of unexpected lung metastasis.,” Case reports in oncology, vol. 5, no. 2. pp. 332–338, May 2012, doi: 10.1159/000339607.
[13] J. Albores-Saavedra, D. E. Henson, and K. Batich, “Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix,” Am. J. Surg. Pathol., vol. 33, no. 8, pp. 1259–1260, 2009, doi: 10.1097/PAS.0b013e3181a1b59e.
[14] R. E. Rossi et al., “Goblet cell appendiceal tumors - Management dilemmas and long-term outcomes,” Surg. Oncol., vol. 24, no. 1, pp. 47–53, 2015, doi: 10.1016/j.suronc.2015.01.001.
[15] L. H. Tang et al., “Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix.,” Am. J. Surg. Pathol., vol. 32, no. 10, pp. 1429–1443, Oct. 2008, doi: 10.1097/PAS.0b013e31817f1816.
[16] S. B. Edge, “AJCC cancer staging manual,” Springer, vol. 7, pp. 97–100, 2010.
[17] K. O. Alsaad, S. Serra, A. Schmitt, A. Perren, and R. Chetty, “Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix.,” Endocr. Pathol., vol. 18, no. 1, pp. 16–22, 2007, doi: 10.1007/s12022-007-0004-x.
[18] E. Liu, D. A. Telem, R. R. P. Warner, A. Dikman, and C. M. Divino, “The role of Ki-67 in predicting biological behavior of goblet cell carcinoid tumor in appendix.,” Am. J. Surg., vol. 202, no. 4, pp. 400–403, Oct. 2011, doi: 10.1016/j.amjsurg.2010.08.036.
[19] A. Gupta, T. Patel, P. Dargar, and M. Shah, “Metastatic appendiceal goblet cell carcinoid masquerading as mucinous adenocarcinoma in effusion cytology: A diagnostic pitfall.,” Journal of cytology, vol. 30, no. 2. India, pp. 136–138, Apr. 2013, doi: 10.4103/0970-9371.112659.
[20] N. Holt and H. Grønbæk, “Goblet cell carcinoids of the appendix.,” ScientificWorldJournal., vol. 2013, p. 543696, 2013, doi: 10.1155/2013/543696.
[21] A. K. Clift et al., “Goblet cell carcinomas of the appendix: Rare but aggressive neoplasms with challenging management,” Endocr. Connect., vol. 7, no. 2, pp. 268–277, 2018, doi: 10.1530/EC-17-0311.
[22] S. J. Kowalsky et al., “Omission of Right Hemicolectomy May be Safe for Some Appendiceal Goblet Cell Adenocarcinomas: A Survival Analysis of the National Cancer Database.,” Ann. Surg. Oncol., vol. 28, no. 13, pp. 8916–8925, Dec. 2021, doi: 10.1245/s10434-021-10191-y.
[23] K. Zakka et al., “Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?,” Surg. Oncol., vol. 36, pp. 120–129, 2021, doi: https://doi.org/10.1016/j.suronc.2020.12.003.
[24] I. H. Olsen et al., “Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients,” PLoS One, vol. 10, no. 2, p. e0117627, Feb. 2015, [Online]. Available: https://doi.org/10.1371/journal.pone.0117627.
[25] N. R. Sluiter et al., “Chemotherapy ( HIPEC ) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas : Propensity Score e Matched Analysis of Centers in the,” Clin. Colorectal Cancer, vol. 19, no. 3, pp. e87–e99, 2020, doi: 10.1016/j.clcc.2020.01.002.
[26] Y. Berger et al., “Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma.,” Ann. Surg. Oncol., vol. 28, no. 3, pp. 1777–1785, Mar. 2021, doi: 10.1245/s10434-020-09064-7.
[27] K. Zambrano-Vera et al., “Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).,” Ann. Surg. Oncol., vol. 27, no. 1, pp. 179–187, Jan. 2020, doi: 10.1245/s10434-019-07932-5.
[28] A. H. Madsen et al., “Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study,” Ann. Surg. Oncol., vol. 25, no. 2, pp. 422–430, 2018, doi: 10.1245/s10434-017-6272-x.
[2] K. Walsh, N. Ojha, A. Nat, L. Gitto, and V. Untanu, “A Rare Presentation of Appendiceal Carcinoma.,” Cureus, vol. 13, no. 7. p. e16370, Jul. 2021, doi: 10.7759/cureus.16370.
[3] M. L. McGory, M. A. Maggard, H. Kang, J. B. O’Connell, and C. Y. Ko, “Malignancies of the appendix: beyond case series reports.,” Dis. Colon Rectum, vol. 48, no. 12, pp. 2264–2271, Dec. 2005, doi: 10.1007/s10350-005-0196-4.
[4] K. J. Kelly, “Management of Appendix Cancer,” Clin. Colon Rectal Surg., vol. 28, no. 4, pp. 247–255, 2015, doi: 10.1055/s-0035-1564433.
[5] U.-F. Pape et al., “ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.,” Neuroendocrinology, vol. 95, no. 2, pp. 135–156, 2012, doi: 10.1159/000335629.
[6] M. J. Snyder, M. Guthrie, and S. Cagle, “Acute Appendicitis: Efficient Diagnosis and Management.,” Am. Fam. Physician, vol. 98, no. 1, pp. 25–33, Jul. 2018.
[7] A. Lamarca et al., “Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence.,” Neuroendocrinology, vol. 103, no. 5, pp. 500–517, 2016, doi: 10.1159/000440725.
[8] S. Edition, S. B. Edge, and D. R. Byrd, “AJCC cancer staging manual,” AJCC cancer staging Man., 2017.
[9] T. H. Pham, B. Wolff, S. C. Abraham, and E. Drelichman, “Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience.,” Ann. Surg. Oncol., vol. 13, no. 3, pp. 370–376, Mar. 2006, doi: 10.1245/ASO.2006.02.016.
[10] K. Palmer et al., “Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry,” Front. Oncol., vol. 12, no. July, pp. 1–14, 2022, doi: 10.3389/fonc.2022.915028.
[11] M. Yozu et al., “Histologic and Outcome Study Supports Reclassifying Appendiceal Goblet Cell Carcinoids as Goblet Cell Adenocarcinomas, and Grading and Staging Similarly to Colonic Adenocarcinomas.,” Am. J. Surg. Pathol., vol. 42, no. 7, pp. 898–910, Jul. 2018, doi: 10.1097/PAS.0000000000001056.
[12] M. Pericleous et al., “Appendiceal goblet cell carcinoid tumour: a case of unexpected lung metastasis.,” Case reports in oncology, vol. 5, no. 2. pp. 332–338, May 2012, doi: 10.1159/000339607.
[13] J. Albores-Saavedra, D. E. Henson, and K. Batich, “Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix,” Am. J. Surg. Pathol., vol. 33, no. 8, pp. 1259–1260, 2009, doi: 10.1097/PAS.0b013e3181a1b59e.
[14] R. E. Rossi et al., “Goblet cell appendiceal tumors - Management dilemmas and long-term outcomes,” Surg. Oncol., vol. 24, no. 1, pp. 47–53, 2015, doi: 10.1016/j.suronc.2015.01.001.
[15] L. H. Tang et al., “Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix.,” Am. J. Surg. Pathol., vol. 32, no. 10, pp. 1429–1443, Oct. 2008, doi: 10.1097/PAS.0b013e31817f1816.
[16] S. B. Edge, “AJCC cancer staging manual,” Springer, vol. 7, pp. 97–100, 2010.
[17] K. O. Alsaad, S. Serra, A. Schmitt, A. Perren, and R. Chetty, “Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix.,” Endocr. Pathol., vol. 18, no. 1, pp. 16–22, 2007, doi: 10.1007/s12022-007-0004-x.
[18] E. Liu, D. A. Telem, R. R. P. Warner, A. Dikman, and C. M. Divino, “The role of Ki-67 in predicting biological behavior of goblet cell carcinoid tumor in appendix.,” Am. J. Surg., vol. 202, no. 4, pp. 400–403, Oct. 2011, doi: 10.1016/j.amjsurg.2010.08.036.
[19] A. Gupta, T. Patel, P. Dargar, and M. Shah, “Metastatic appendiceal goblet cell carcinoid masquerading as mucinous adenocarcinoma in effusion cytology: A diagnostic pitfall.,” Journal of cytology, vol. 30, no. 2. India, pp. 136–138, Apr. 2013, doi: 10.4103/0970-9371.112659.
[20] N. Holt and H. Grønbæk, “Goblet cell carcinoids of the appendix.,” ScientificWorldJournal., vol. 2013, p. 543696, 2013, doi: 10.1155/2013/543696.
[21] A. K. Clift et al., “Goblet cell carcinomas of the appendix: Rare but aggressive neoplasms with challenging management,” Endocr. Connect., vol. 7, no. 2, pp. 268–277, 2018, doi: 10.1530/EC-17-0311.
[22] S. J. Kowalsky et al., “Omission of Right Hemicolectomy May be Safe for Some Appendiceal Goblet Cell Adenocarcinomas: A Survival Analysis of the National Cancer Database.,” Ann. Surg. Oncol., vol. 28, no. 13, pp. 8916–8925, Dec. 2021, doi: 10.1245/s10434-021-10191-y.
[23] K. Zakka et al., “Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?,” Surg. Oncol., vol. 36, pp. 120–129, 2021, doi: https://doi.org/10.1016/j.suronc.2020.12.003.
[24] I. H. Olsen et al., “Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients,” PLoS One, vol. 10, no. 2, p. e0117627, Feb. 2015, [Online]. Available: https://doi.org/10.1371/journal.pone.0117627.
[25] N. R. Sluiter et al., “Chemotherapy ( HIPEC ) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas : Propensity Score e Matched Analysis of Centers in the,” Clin. Colorectal Cancer, vol. 19, no. 3, pp. e87–e99, 2020, doi: 10.1016/j.clcc.2020.01.002.
[26] Y. Berger et al., “Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma.,” Ann. Surg. Oncol., vol. 28, no. 3, pp. 1777–1785, Mar. 2021, doi: 10.1245/s10434-020-09064-7.
[27] K. Zambrano-Vera et al., “Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).,” Ann. Surg. Oncol., vol. 27, no. 1, pp. 179–187, Jan. 2020, doi: 10.1245/s10434-019-07932-5.
[28] A. H. Madsen et al., “Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study,” Ann. Surg. Oncol., vol. 25, no. 2, pp. 422–430, 2018, doi: 10.1245/s10434-017-6272-x.
Published
2022-04-15
Section
Articles
